Quoin Pharmaceuticals (QNRX) Research & Development (2021 - 2026)
Quoin Pharmaceuticals (QNRX) posted Research & Development of $3.63 million for the quarter ended Jun 30, 2026, up 76.9% from $2.05 million a year earlier and up 5.6% from the prior quarter.
Quoin Pharmaceuticals (QNRX) Research & Development (2021 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Research & Development at Quoin Pharmaceuticals was $12.44 million, up 89.8% year-over-year; for the year ended Dec 31, 2025, it came in at $9.8 million, up 172.1% from the prior year.
- Annual Research & Development has increased for six consecutive years, with a five-year compound annual growth rate of 109.3% (years ended Dec 2020 to Dec 2025).
- In prior years, Quoin Pharmaceuticals' Research & Development was $3.6 million in the year ended Dec 31, 2024 (+8.9%), $3.31 million in the year ended Dec 31, 2023 (+23.8%), $2.67 million in the year ended Dec 31, 2022 (+71.0%) and $1.56 million in the year ended Dec 31, 2021 (+540.1%).
- The figure for the quarter ended Jun 30, 2026 stands as the highest quarterly Research & Development in data going back to the quarter ended Jun 30, 2021.
- On a year-over-year basis, Research & Development has increased in each of the last eight quarters, with growth averaging 114.2% over the last eight quarters.
- The strongest year-over-year quarter for Research & Development in the past five years was the quarter ended Jun 30, 2025, with growth of 249.0%; the weakest was the quarter ended Dec 31, 2022, with a decline of 39.1%.
- According to Business Quant data, Research & Development for the three prior quarters was $3.43 million (quarter ended Mar 31, 2026), $3.1 million (quarter ended Dec 31, 2025) and $2.28 million (quarter ended Sep 30, 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,146.94 Bn | 1,115.53 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 624.96 Bn | 543.49 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 510.15 Bn | 483.27 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 366.13 Bn | 320.51 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 297.75 Bn | 261.74 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.93 Bn | 235.62 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 236.51 Bn | 191.91 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 194.27 Bn | 168.47 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 171.74 Bn | 118.39 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Quoin Pharmaceuticals | 334,688.69 | -45.13 Mn | - | 3.63 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.63 Mn |
| Mar 31, 2026 | 3.43 Mn |
| Dec 31, 2025 | 3.10 Mn |
| Sep 30, 2025 | 2.28 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 587,503.00 |
| Mar 31, 2024 | 885,298.00 |
| Dec 31, 2023 | 832,391.00 |
| Sep 30, 2023 | 758,759.00 |
| Jun 30, 2023 | 625,104.00 |
| Mar 31, 2023 | 1.09 Mn |
| Dec 31, 2022 | 613,067.00 |
| Sep 30, 2022 | 745,506.00 |
| Jun 30, 2022 | 726,694.00 |
| Mar 31, 2022 | 587,569.00 |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 259,996.00 |
Quoin Pharmaceuticals Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=QNRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "QNRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=QNRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();